Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)

NCT ID: NCT00555737

Last Updated: 2019-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

102 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-11-30

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine how well capsule endoscopy identifies changes in the small bowel mucosa of celiac disease patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gluten-sensitive enteropathy (GSE), also known as celiac disease, is characterized by abnormal small intestinal mucosa arising as a consequence of an inappropriate inflammatory response to ingested gluten in susceptible individuals.

These changes cause a loss of absorptive capacity which in turn leads to variable degrees of malabsorption. A person suffering from celiac may have symptoms ranging from mild iron deficiency anemia to severe diarrhea and weight loss. Characteristically, removal of gluten from the diet is followed by resolution of the mucosal changes and the symptoms.

Celiac disease is suspected on the basis of clinical signs and symptoms, and is generally confirmed by serological testing and small bowel biopsy. Patients with suspected celiac disease undergo upper GI endoscopy with mucosal biopsy of the duodenum, in order to detect the characteristic histological changes.

Although the main role for endoscopy in GSE is to obtain tissue for histological examination, a variety of endoscopic changes have been described in these patients,such as nodularity of the mucosa and 'scalloping' or loss of the duodenal mucosal folds.

The GivenĀ® Diagnostic System can visually investigate the small bowel, producing high-quality images of the mucosa, which might be able to detect villous atrophy and thus could be used in the assessment of patients with GSE. Whereas upper GI endoscopy is invasive, often requires sedation and may be uncomfortable, Capsule Endoscopy is less invasive, convenient to use and does not require sedation.

Capsule Endoscopy could become an important tool for the non-invasive assessment of small bowel mucosa in GSE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Celiac Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capsule Endoscopy

GivenĀ® Diagnostic system with Pillcam SB

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age is 18 years or older
* Patient agrees to sign the Informed Consent Form
* Patient has positive celiac serology or negative celiac serology + IgA deficiency and suffers from one or more of the following symptoms and/or abdominal biochemical values:

1. Chronic diarrhea
2. Weight loss
3. Abdominal cramps
4. History of spontaneous abortion
5. Iron deficiency anemia
6. Osteoporosis
7. Infertility
8. Hypoalbuminaemia
9. Low cholesterol
10. Low prothrombin activity

Exclusion Criteria

* Patient is known or is suspected to suffer from intestinal obstruction.
* Patient has a cardiac pacemaker or other electro-medical device.
* Patient suffers from severe swallowing disorder or Zenker's diverticulum
* Patient has any condition, which precludes compliance with study and/or device instructions.
* Female patient is pregnant
* Patient suffers from life threatening conditions
* Patient is currently participating in another clinical study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic - MITG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Given Imaging Ltd.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roberto de Franchis, MD, Prof.

Role: PRINCIPAL_INVESTIGATOR

Ospedale Maggiore - Policlinico, Milano, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Massachusetts Memorial Medical Center

Worcester, Massachusetts, United States

Site Status

University of Tampere Medical School

Tampere, , Finland

Site Status

Ospedale Maggiore - Policlinico

Milan, , Italy

Site Status

Universita Cattolica del Sacro Cuore

Rome, , Italy

Site Status

San Giovanni A.S. Hospital

Torino, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Finland Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MA-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.